Safety Study of Cenderitide in Stable Chronic Heart Failure

Summary

Planned enrollment is approximately twelve subjects with stable chronic heart failure. Enrolled subjects will receive up to eight sequential days of continuous, stepwise, dose increasing, subcutaneous (SQ) infusions of open-label cenderitide via the Insulet Drug Delivery System. Planned infusion rates of cenderitide will be administered to subjects continuously during four, 48-hour infusion periods.

Timeline

Start

2015-01

Primary completion

2015-04-02

Completion

2015-04-02

Drugs

Indications